| Literature DB >> 17958896 |
Gladys Block1, Christopher D Jensen, Edward P Norkus, Tapashi B Dalvi, Les G Wong, Jamie F McManus, Mark L Hudes.
Abstract
BACKGROUND: Dietary supplement use in the United States is prevalent and represents an important source of nutrition. However, little is known about individuals who routinely consume multiple dietary supplements. This study describes the dietary supplement usage patterns, health, and nutritional status of long-term multiple dietary supplement users, and where possible makes comparisons to non-users and multivitamin/mineral supplement users.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17958896 PMCID: PMC2164946 DOI: 10.1186/1475-2891-6-30
Source DB: PubMed Journal: Nutr J ISSN: 1475-2891 Impact factor: 3.271
Micronutrient assay methods.
| Analyte | Method | Ref. |
| RBC folate (nmol/L) | Quantaphase Folate Radioassay Kit, Bio-Rad Laboratories | 7 |
| Retinol (μg/dL) | Isocratic reversed-phase HPLC with UV/Vis detection | 8 |
| Ascorbic acid (mg/dL) | Isocratic reversed-phase HPLC with Electrochemical detection* | 7 |
| Alpha tocopherol (mg/dL) | Isocratic reversed-phase HPLC with UV/Vis detection | 8 |
| Alpha carotene (μg/dL) | Isocratic reversed-phase HPLC with UV/Vis detection | 8 |
| Beta carotene (μg/dL) | Isocratic reversed-phase HPLC with UV/Vis detection | 8 |
| Ferritin (μg/L) | Quantlmune Ferritin IRMA kit, Bio-Rad Laboratories | 7 |
| 25-hydroxyvitamin D (nmol/L) | Quantlmune Ferritin IRMA kit, Bio-Rad Laboratories | 7 |
| Homocysteine (μmol/L) | Isocratic reversed-phase HPLC with Fluorescence detection | 9 |
| C-reactive protein (mg/L) | Latex-enhanced nephelometry, Behring Nephelometer Analyzer for NHANES assays and Hitachi 917 Analyzer for Multiple Supp user assays | 7 |
| Total cholesterol (mg/dL) | Timed endpoint, coupled enzymatic methodology | 10 |
| LDL-cholesterol (mg/dL) | Calculated** | 7 |
| HDL-cholesterol (mg/dL) | Polyanion/divalent cation precipitation of other lipoproteins followed by timed endpoint, coupled enzymatic methodology | 10 |
| Triglycerides (mg/dL) | Timed endpoint, coupled enzymatic methodology | 11 |
*Use of 1 part serum plus 1 part 10% meta-phosphoric acid for Multiple Supp users versus NHANES use of 1 part serum plus 4 part meta-phosphoric acid.
** Calculated: LDL-cholesterol = [total cholesterol - HDL-cholesterol - (triglycerides/5)] Ref = reference, LDL = low-density lipoprotein, HDL = high-density lipoprotein.
Characteristics of the three supplement user groups: multiple dietary supplement users (Multiple Supp) from Shaklee, and multivitamin/mineral users (Single Supp) and non-users (No Supp) from NHANES 2001–2002.
| Characteristic | No Supp n = 602 | Single Supp n = 176 | Multiple Supp n = 278 | P-value* |
| Sex (% female) | 40.5 | 44.6 | 57.9 | <0.0001 |
| Race (% white) | 100 | 100 | 98.9 | |
| Age, years (mean, SE) | 53.7 (0.59) | 57.0 (0.99) | 63.3 (0.48) | <0.001 |
| BMI, kg/m2 (mean, SE) | 29.4 (0.32) | 27.9 (0.46) | 25.9 (0.31) | <0.001 |
| Education (%) | <0.0001 | |||
| < High School Graduate | 16.8 | 14.7 | 1.8 | |
| High School Graduate | 29.1 | 30.1 | 12.2 | |
| > High School Graduate | 54.2 | 55.2 | 86.0 | |
| Annual income (%) | <0.0001 | |||
| < $30,000 | 19.7 | 17.3 | 2.5 | |
| $30,000–39,999 | 16.4 | 14.4 | 6.8 | |
| $40,000–49,999 | 18.2 | 19.9 | 4.7 | |
| $50,000–59,999 | 6.9 | 10.2 | 13.3 | |
| $60,000–69,999 | 6.3 | 3.3 | 10.8 | |
| ≥ $70,000 | 32.6 | 34.9 | 61.9 |
*Differences among the supplement user groups were evaluated using chi-square methods for categorical variables and one-way analysis of variance for continuous variables. BMI = body mass index.
Dietary supplement usage patterns of long-term users of multiple dietary supplements (Multiple Supp users).
| Dietary supplement type | Average daily usage | % of women who were daily users | % of men who were daily users |
| Multivitamin/mineral (with or without iron) | * | 89.5 | 84.7 |
| B-Complex | † | 87.7 | 79.5 |
| Vitamin C | 1000 mg/d | 86.4 | 80.3 |
| Vitamin E (d-alpha tocopherol and mixed tocopherols) | 800 IU/d | 79.0 | 74.4 |
| Carotenoids | ‡ | 79.6 | 74.4 |
| Flavonoids (from a variety of sources) | 362 mg/d | 86.4 | 52.1 |
| Calcium with vitamin D | § | 81.5 | 68.4 |
| Zinc | 15 mg/d | 48.2 | 55.6 |
| Lecithin | 3.1 g/d | 71.6 | 66.7 |
| Alfalfa ( | 2.85 g/d | 75.9 | 70.9 |
| Garlic ( | 1 g/d | 49.4 | 54.7 |
| Omega-3 fatty acids (from fish oil) | 1000 mg/d | 81.5 | 73.5 |
| Coenzyme Q10 with resveratrol | # | 69.8 | 64.1 |
| Soy protein isolate | 14 g/d | 46.9 | 55.6 |
| Glucosamine hydrochloride | 1500 mg/d | 59.3 | 57.3 |
| Saw palmetto extract ( | 320 mg/d | 1.9 | 67.5 |
| Gamma linolenic acid (from borage seed oil) | 180 mg/d | 62.4 | 35.0 |
| Probiotic supplement (from | †† | 50.0 | 32.5 |
| Herbal immune supplement | ‡‡ | 60.5 | 58.1 |
*35–200% of the Daily Value for 25 vitamin and minerals and also includes 5 trace minerals.
†200–2700% of the Daily Value for 8 B vitamins.
‡5000 IU/d vitamin A as beta carotene, 5 mg/d lycopene, 5 mg/d lutein, 1.5 mg/d alpha carotene, 200 mcg/d zeaxanthin, 400 mcg/d astaxanthin.
§1500 mg/d calcium, 600 IU/d vitamin D, 600 mcg/d vitamin K, 600 mg/d magnesium, and <15% of the Daily value for zinc, copper, and manganese.
#30 mg/d coenzyme Q10 and 640 mcg/d resveratrol.
††250 million/d Bifidobacterium longum and 250 million/d Lactobacillus acidophilus.
‡‡500 mg/d plant extracts from pumpkin seed (Curcubita moschata), safflower flower (Carthamus tinctorius), asian plantain seed (Plantago asiatica), Japanese honeysuckle flower (Lonicera japonica).
Serum nutrient and biomarker concentrations of a sample of long-term users of multiple dietary supplements (Multiple Supp), and of multivitaminmineral users (Single Supp) and non-users (No Supp) from NHANES 2001–2002 and NHANES III 1988–1994.
| Characteristic | No Supp n = 602 | Single Supp N = 176 | Multiple Supp N = 278 | p-value* |
| Mean (SE) | ||||
| NUTRIENTS | ||||
| RBC folate (nmol/L)‡ | 646.7 (8.9) a | 891.1 (30.7) b | 1153.4 (11.8) c | <0.001 |
| Retinol (μg/dL)† | 59.2 (0.5) a | 64.3 (0.7) b | 65.0 (1.0) b | <0.001 |
| Ascorbic acid (mg/dL)† | 0.66 (0.02) a | 0.94 (0.02) b | 1.62 (0.03) c | <0.001 |
| Alpha tocopherol (mg/dL)† | 1.1 (0.01) a | 1.4 (0.02) b | 2.9 (0.06) c | <0.001 |
| Alpha carotene (μg/dL)† | 4.5 (0.1) a | 5.9 (0.2) b | 27.5 (1.3) c | <0.001 |
| Beta carotene (μg/dL)† | 18.5 (0.3) a | 27.0 (1.2) b | 62.7 (2.8) c | <0.001 |
| Ferritin (μg/L)‡ Male | 198.2 (6.1) a | 205.2 (12.6) a | 117.6 (5.9) b | <0.001 |
| Ferritin (μg/L)‡ Female | 101.7 (7.1) a | 74.9 (8.4) b | 117.4 (3.3) c | <0.001 |
| 25-hydroxyvitamin D (nmol/L) | 131.4 (45.3)§ | |||
| BIOMARKERS | ||||
| Homocysteine (μmol/L)‡ | 9.6 (0.2) a | 9.1 (0.5) a | 6.1 (0.3) b | <0.001 |
| C-reactive protein (mg/dL)‡ | 0.46 (0.04) a | 0.32 (0.03) b | 0.19(0.03) c | <0.01 |
| Total cholesterol (mg/dL)‡ | 211.5 (2.9) a | 212.1 (3.6) a | 203.1 (2.7) b | <0.05 |
| LDL-cholesterol (mg/dL)‡ | 125.1 (2.8) | 129.5 (4.2) | 122.1 (2.6) | NS (>0.05) |
| HDL-cholesterol (mg/dL)‡ | 50.9(0.5) a | 53.3 (1.4) a | 57.5 (1.1) b | <0.001 |
| Ratio total-cholesterol to HDL-cholesterol‡ | 4.5 (0.07) a | 4.3 (0.13) a | 4.0 (0.09) b | <0.001 |
| Triglycerides (mg/dL)‡ | 180.1 (16.7) a | 145.3 (9.4) a | 121.0 (6.8) b | < 0.01 |
*Multiple regression techniques were employed to examine differences in nutrient and biomarker concentrations of user groups. Differences in nutrient concentrations were adjusted for sex and age. Differences in biomarker concentrations were further adjusted for age2, education, income and income2, and body mass index (BMI). P-values represent the statistical significance for comparisons of user group means with different letters; if these comparisons varied in significance level, the most significant is shown.
†Data obtained from NHANES III 1988–1994.
‡Data obtained from NHANES 2001–2002.
§Comparable 25–hydroxy vitamin D data not available from NHANES.
LDL = low-density lipoprotein, HDL = high-density lipoprotein.
Risk of suboptimal or elevated serum biomarker concentrations and elevated blood pressure by supplement user group.
| Outcome | Cases: n/(%) | OR* | 95% CI* |
| Homocysteine (>9 μmol/L) | |||
| Multiple Supp users | 30/(10.9) | 0.11 | 0.06–0.19 |
| Single Supp users | 69/(37.0) | 0.53 | 0.34–0.83 |
| No Supp users | 282/(45.3) | 1.00 | |
| C-reactive protein (>0.3 mg/dL) | |||
| Multiple Supp users | 0/(0.00) | † | † |
| Single Supp users | 51/(30.6) | 0.66 | 0.40–1.09 |
| No Supp users | 230/(41.3) | 1.00 | |
| Total cholesterol (>200 mg/dL) | |||
| Multiple Supp users | 145/(52.5) | 0.78 | 0.56–1.09 |
| Single Supp users | 89/(57.8) | 1.08 | 0.72–1.62 |
| No Supp users | 291/(54.3) | 1.00 | |
| HDL-cholesterol (<40 mg/dL males, <50 mg/dL females) | |||
| Multiple Supp users | 44/(15.8) | 0.50 | 0.33–0.75 |
| Single Supp users | 40/(24.5) | 0.58 | 0.41–0.83 |
| No Supp users | 203/(38.0) | 1.00 | |
| Ratio total cholesterol to HDL-cholesterol (<5) | |||
| Multiple Supp users | 35/(12.7) | 0.49 | 0.32–0.74 |
| Single Supp users | 48/(35.3) | 1.05 | 0.64–1.73 |
| No Supp users | 189/(36.5) | 1.00 | |
| Triglycerides (≥150 mg/dL) | |||
| Multiple Supp users | 52/(18.8) | 0.44 | 0.27–0.71 |
| Single Supp users | 31/(41.5) | 0.99 | 0.50–1.94 |
| No Supp users | 157/(42.8) | 1.00 | |
| LDL-cholesterol (>130 mg/dL) | |||
| Multiple Supp users | 109/(39.5) | 0.96 | 0.56–1.65 |
| Single Supp users | 32/(47.6) | 1.19 | 0.70–2.03 |
| No Supp users | 101/(42.7) | 1.00 | |
| Blood Pressure (DBP>80 mmHg or SBP>120 mmHg) | |||
| Multiple Supp users | 154/(55.6) | 0.61 | 0.41–0.92 |
| Single Supp users | 117/(71.2) | 1.34 | 0.88–2.03 |
| No Supp users | 353/(64.6) | 1.00 |
* Logistic regression methods were used to estimate odds ratios (OR) with 95% confidence intervals (CI), adjusted as in footnote to Table 4. The referent group for risk estimation was the No Supp group.
†OR and 95% CI not estimable because zero events in the user group. Number and percent shown instead.
HDL = high-density lipoprotein, LDL = low-density lipoprotein, DBP = diastolic blood pressure, SBP = systolic blood pressure.
Risk of prevalent disease, by supplement user group.
| Outcome | Cases: n/(%) ** | OR* | 95% CI* |
| Diabetes | |||
| Multiple Supp users | 8/(2.9) | 0.27 | 0.12–0.59 |
| Single Supp users | 23/(11.1) | 1.11 | 0.74–1.67 |
| No Supp users | 70/(8.5) | 1.00 | |
| Coronary Heart Disease | |||
| Multiple Supp users | 14/(5.0) | 0.48 | 0.22–1.09 |
| Single Supp users | 17/(7.1) | 1.08 | 0.52–2.25 |
| No Supp users | 47/(5.6) | 1.00 | |
| Heart Attack | |||
| Multiple Supp users | 7/(2.5) | 0.51 | 0.18–1.41 |
| Single Supp users | 16/(7.6) | 1.76 | 0.90–3.42 |
| No Supp users | 44/(4.4) | 1.00 | |
| Angina | |||
| Multiple Supp users | 6/(2.2) | 0.41 | 0.14–1.18 |
| Single Supp users | 12/(6.8) | 1.71 | 0.82–3.59 |
| No Supp users | 35/(4.7) | 1.00 | |
| Congestive Heart Failure | |||
| Multiple Supp users | 4/(1.4) | 0.73 | 0.18–2.95 |
| Single Supp users | 9/(2.8) | 0.88 | 0.26–2.97 |
| No Supp users | 31/(3.5) | 1.00 | |
| Stroke | |||
| Multiple Supp users | 5/(1.8) | 1.42 | 0.39–5.17 |
| Single Supp users | 6/(2.6) | 1.26 | 0.34–4.67 |
| No Supp users | 29/(2.5) | 1.00 | |
| Arthritis | |||
| Multiple Supp users | 88/(31.7) | 1.00 | 0.69–1.46 |
| Single Supp users | 71/(31.8) | 1.23 | 0.77–1.98 |
| No Supp users | 189/(26.7) | 1.00 | |
| Emphysema | |||
| Multiple Supp users | 3/(1.1) | 0.55 | 0.09–3.41 |
| Single Supp users | 4/(1.8) | 0.73 | 0.32–1.64 |
| No Supp users | 23/(2.3) | 1.00 | |
| Health Status† | |||
| Multiple Supp users | 44/(15.8) | 0.26 | 0.17–0.41 |
| Single Supp users | 86/(44.4) | 0.75 | 0.45–1.23 |
| No Supp users | 302/(50.9) | 1.00 |
* Logistic regression methods were used to estimate odds ratios (OR) with 95% confidence intervals (CI), adjusted for sex, age and age2, education, income and income2, and body mass index. The referent group for risk estimation was the No Supp group.
** Number of events, weighted percent
†Self-assessed as 'good, fair, or poor' versus 'excellent or very good.'